KISQALI® (ribociclib) prescribing information (external link)
TAFINLAR® (dabrafenib) + MEKINIST® (trametinib) prescribing information (external link)
SANDOSTATIN® LAR® (octreotide acetate) prescribing information (external link)
This page includes promotional content created and funded by Novartis Pharmaceuticals UK Ltd. Novartis products may be mentioned.
Oncology
KISQALI® (ribociclib)
aBC resources
Video
13 mins 49 secs
Prof. Peter Fasching patient case study
Video
6 mins 11 secs
Dr Caroline Michie patient case study
Video
13 mins 28 secs
Dr Mark Verrill patient case study
Video
4 mins 44 secs
Dr Mark Tuthill patient case study
Video
6 mins 36 secs
Dr Alastair Thomson patient case study
Video
7 mins 6 secs
Bleddyn Edwards patient case study
Video
15 mins 15 secs
Dr Vivek Misra assessment of frailty and CDK4/6i eligibility
Video
4 mins 32 secs
Dr Vivek Misra treatment goals for HR+/HER2– aBC
Video
2 mins 2 secs
Prof. Peter Fasching treatment goals in aBC
eBC resources
Video
9 mins 13 secs
Prof. Peter Fasching 4-year outcomes from the NATALEE trial
Video
8 mins 46 secs
Prof. Stephen Johnston risk of recurrence in HR+/HER2– eBC
Video
10 mins 41 secs
Tej Quine virtually assessed pathway (VAP) clinic
Video
11 mins 41 secs
Dr Hartmut Kristeleit: Patient case study
Video
13 mins 47 secs
Dr Elsa Papadimitraki: Patient case study
Video
17 mins 55 secs
Group Panel discussion
TAFINLAR® (dabrafenib) + MEKINIST® (trametinib)
SANDOSTATIN® LAR® (octreotide acetate)
Video
7 mins 20 secs
How to administer and prepare SANDOSTATIN LAR
Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Novartis online through the pharmacovigilance intake (PVI) tool at www.novartis.com/report, or alternatively email [email protected] or call 01276 698370.
